document: Since GBMs are radioresistant malignancies, and most GBM recurrences occur after radiotherapy. Thus, the effectiveness of radiotherapy can be enhanced by target gene-silencing using siRNA or miRNA, which has recently attracted attention. However, the difficulty in precisely tuning the composition and RNA loading in nanoparticles leads to batch-to-batch variations of the RNA drugs, thus significantly restricting their clinical translation. We have developed a biological manufacturing technique to